Active Substance: Amikacin (as sulfate).
Overview
Welcome to Dwaey, specifically on MIKACIN 500mg/2ml I.M/I.V page.
This medicine contains an important and useful components, as it consists of
Amikacin (as sulfate)is available in the market in concentration
Amikacin
Renal impairment; vertigo, tinnitus. Discontinue if signs of ototoxicity, neurotoxicity or hypersensitivity occurs; lactation. Safety has not been established for treatment period >14 days. Monitor renal function before and during treatment. Lactation: excretion in milk unknown/not recommended
Tuberculosis, Complicated and recurrent urinary tract infections, Severe Gram-negative infections, Non-tubercular mycobacterial infections, Bacterial septicemia, Infections of the respiratory tract, Bones and joints, Central nervous system and skin and soft tissue, Intra-abdominal infections, Burns, Postoperative infections, Meningitis, Peritonitis, Neonatal sepsis
Pregnancy, perforated ear drum, myasthenia gravis, hypersensitivity.
1-10% Neurotoxicity,Nephrotoxicity (if trough >10 mg/L),Ototoxicity <1% Hypotension,Headache,Drug fever,Rash,Nausea,Vomiting,Eosinophilia,Paresthesia,Tremor,Arthralgia,Weakness,Allergic reaction Potentially Fatal: Ototoxicity, nephrotoxicity, neuromuscular blockade.
4
Amikacin binds to 30S ribosomal subunits of susceptible bacteria, thus inhibiting its protein synthesis.
Amphotericin B may lead to increased nephrotoxicity and reduced clearance of amikacin when used together. Potentially Fatal: Increased ototoxic or nephrotoxic effects with other nephrotoxic or ototoxic drugs. Enhanced neuromuscular blockade with neuromuscular blocking drugs. Increased risk of ototoxicity with potent diuretics.
Information not available